ESMO 2016

Combination of chemotherapy with dasatinib is effective in achieving long-term remission for in Ph+

First-line Nivolumab Not Superior to Chemo for Stage IV/Recurrent PD-L1+ NSCLC

By

Jason Hoffman, PharmD, RPh

October 12, 2016

First-line treatment with nivolumab was not superior to investigator’s choice of platinum-based doublet chemotherapy for progression-free survival.

Cisplatin or carboplatin in combination with pemetrexed for non-small cell lung carcinoma demonstrat

Full-dose Neoadjuvant Anthracycline + Ifosfamide Improves OS in High-risk Soft Tissue Sarcoma

By

Jason Hoffman, PharmD, RPh

October 12, 2016

Treatment with a full-dose regimen consisting of an anthracycline plus ifosfamide administered for 3 courses prior to surgery improves relapse-free and overall survival.

The FDA has approved the first blood-based genetic test that can detect EGFR gene mutations in non-s

Atezolizumab Improves Overall Survival Versus Docetaxel in NSCLC

By

Jason Hoffman, PharmD, RPh

October 12, 2016

Treatment with atezolizumab resulted in a statistically significant and clinically relevant improvement in overall survival.

Results from a small retrospective study showed that percutaneous microwave ablation (MWA) had a tec

Niraparib Maintenance Prolongs PFS in Recurrent Ovarian Cancer

By

Jason Hoffman, PharmD, RPh

October 12, 2016

Maintenance therapy with niraparib significantly prolongs progression-free survival for all study populations of patients with recurrent ovarian cancer.

All postpubertal boys newly diagnosed with cancer should be encouraged to bank their sperm to preser

Adjuvant Sunitinib Prolongs DFS in High-risk Locoregional Renal Cell Carcinoma

By

Jason Hoffman, PharmD, RPh

October 12, 2016

Adjuvant treatment with sunitinib prolonged disease-free survival, and was associated with a manageable safety profile.

Nab-paclitaxel significantly improved progression-free survival and disease control rate in patients

Adjuvant Ipilimumab Improves OS in High-risk Stage III Melanoma

By

Jason Hoffman, PharmD, RPh

October 12, 2016

Adjuvant treatment with ipilimumab significantly improved overall survival among patients with high-risk, stage III melanoma.

A pharmacist-led medication assessment demonstrated high prevalence of polypharmacy and potentially

Adding Ribociclib to Letrozole Improves PFS in HR+ Advanced Breast Cancer

By

Jason Hoffman, PharmD, RPh

October 12, 2016

Adding ribociclib to letrozole is well tolerated, and significantly improves progression-free survival.

Glioma

Dabrafenib Shows Promising Activity in BRAF+ Low-grade Glioma

By

Jason Hoffman, PharmD, RPh

October 11, 2016

Dabrafenib is active and well-tolerated among patients with BRAF V600 mutation-positive pediatric low-grade glioma.

Level of lymph node metastases may be an independent prognostic factor in head and neck squamous cel

Durvalumab Shows Encouraging OS Rates in Advanced HNSCC

By

Jason Hoffman, PharmD, RPh

October 11, 2016

PD-L1 inhibition with durvalumab is associated with encouraging overall survival rates in pretreated HNSCC.

All postpubertal boys newly diagnosed with cancer should be encouraged to bank their sperm to preser

Study Explores Efficacy of Fosaprepitant Regimen Among Patients Receiving MEC

By

Jason Hoffman, PharmD, RPh

October 11, 2016

A 1-day, 3-drug, fosaprepitant-containing regimen is efficacious for preventing chemotherapy-induced nausea and vomiting.

Next post in ESMO 2016

A survey of ethnically diverse women treated for breast cancer has identified a “complete failure” a

Abiraterone Lacks Activity in Recurrent High Grade Serous Epithelial Ovarian Cancer